Cardinal Health, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Cardinal Health, Inc. stock analysis CAH overview
Somewhat Bullish +50

Cardinal Health stock (US14149Y1082): JPMorgan raises price target to $215 - AD HOC NEWS

📈 JPMorgan Chase raised its price target for Cardinal Health (CAH) shares to $215 per share on May 11, 2026.

📉 Despite the analyst upgrade, the stock experienced a 7.8% decline in trading on that same date.

🏆 Zacks Investment Research maintains a "Buy" recommendation (Rank #2) and an "A" grade for value on Cardinal Health.

💊 Cardinal Health operates as the second-largest distributor of pharmaceuticals and medical products in the US, trailing only McKesson by revenue.

📦 In fiscal year 2025, the company reported total revenue of $226.8 billion through its Pharmaceutical and Medical segments.

💉 The Pharmaceutical segment contributes over 75% of revenue, focusing on brand-name drugs, generics, and opioids managed via OptumRx.

🩺 The Medical segment generates income from devices, apparel, surgical kits, gloves, gowns, and at-home patient solutions.

📊 Cardinal Health holds approximately 20% market share in US drug distribution, providing stability amid rising demand for pharmaceuticals.

📉 The company faces margin pressure from drug pricing reforms but expects growth driven by high volume and specialty pharma trends.

👵 Business alignment with aging demographics supports long-term relevance through specialty pharma and home infusion services.

🇺🇸 With over 90% of revenue originating from North America, the stock serves as a proxy for US healthcare spending, projected at $4.9 trillion in 2026.

🏢 Cardinal Health competes in a consolidating sector involving pharmacy benefit managers and hospital systems.

🚫 This article does not constitute investment advice, noting that stocks are volatile financial instruments.

Bullish Signals
  • JPMorgan Chase & Co. raised its price target for Cardinal Health to $215, indicating strong analyst confidence in the stock's value.
  • Zacks awarded Cardinal Health a 'Buy' rating with Rank #2 and a Value grade of 'A', highlighting its financial strength.
  • The company reported record-breaking total revenue of $226.8 billion for the fiscal year ended June 30, 2025.
  • Cardinal Health holds a dominant #2 position in the US medical distribution sector with over 20% market share in drug distribution.
  • Revenue from the Medical segment is being boosted by sustained post-pandemic demand for products like gloves, gowns, and surgical kits.
  • US healthcare spending is projected to reach $4.9 trillion in 2026, providing a stable foundation for Cardinal Health's growth.
  • The company aligns well with demographic trends as its focus on specialty pharma and home infusion supports an aging US population.
Risk Factors
  • Cardinal Health stock declined by 7.8% during the trading session on May 11, 2026, despite a concurrent analyst price target raise.
  • The company operates in the US medical distribution sector which faces margin compression due to ongoing drug pricing reforms.
  • With only 90%+ of revenue coming from North America, Cardinal Health remains highly exposed to domestic economic health and local pharmacy benefit manager trends.
Full Analysis
JPMorgan Chase recently raised its price target on Cardinal Health (NYSE:CAH) to $215 per share, reflecting continued analyst interest in the healthcare distributor's fundamentals. The article contextualizes this bullish rating against a backdrop of recent stock volatility, noting that CAH shares actually saw a 7.8% decline in the session preceding the report. This divergence between the price target hike and intraday price movement suggests investors are weighing the high valuation multiple or future expectations against short-term market fluctuations. Fundamentally, Cardinal Health remains a dominant force in the US healthcare supply chain, holding approximately 20% market share for drug distribution and ranking second only to McKesson by revenue. The company's business is heavily skewed towards pharmaceuticals, which contribute over 75% of its total revenue through brand-name and generic channels, while its medical segment focuses on high-volume items like surgical gloves, gowns, and devices driven by post-pandemic demand. Recent fiscal year data from June 30, 2025, showed massive scale with $226.8 billion in total revenue, underlining its position as a critical logistical backbone for hospitals and pharmacies nationwide. The article highlights that Cardinal Health's growth is tethered to the broader US healthcare market, which CMS projects will reach spending of $4.9 trillion by 2026. Despite potential margin compression from drug pricing reforms, the company benefits from volume growth and its strategic focus on specialty pharmaceuticals and home infusion services, areas aligned with an aging American demographic. Analysts like Zacks continue to endorse the stock with a 'Buy' rating (Zacks Rank #2) and an A grade for value, indicating that the broader investment community believes in the stability of the company's distribution infrastructure against volatile market conditions. The ticker remains listed on the NYSE with over 90% of its revenue generated domestically, making it a primary proxy for US pharmaceutical demand and healthcare supply chain trends.